Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208-16

Affiliations

¹ Nuclear Medicine Unit, Department of Medicine, University of Padua, Padua, Italy. Electronic address: laura.evangelista@unipd.it.
² Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.
³ Urology Unit, Academic Medical Centre Hospital, Udine, Italy.
⁴ Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.

Comment

Laura Evangelista et al. Eur Urol Oncol. 2020 Oct.

. 2020 Oct;3(5):713.

doi: 10.1016/j.euo.2020.06.013. Epub 2020 Jul 18.

¹ Nuclear Medicine Unit, Department of Medicine, University of Padua, Padua, Italy. Electronic address: laura.evangelista@unipd.it.
² Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.
³ Urology Unit, Academic Medical Centre Hospital, Udine, Italy.
⁴ Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.

No abstract available

Comment on

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.